Nervgen Pharma Ord Shs
NGEN3.880USD
+0.050+1.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Nervgen Pharma Ord Shs Company
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shs Info
Ticker SymbolNGEN
Company nameNervGen Pharma Corp
IPO dateMar 13, 2019
CEORogers (Adam H)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
AddressSuite 1703 - 595 Burrard Street
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV7X 1J1
Phone16047225361
Websitehttps://www.nervgen.com/
Ticker SymbolNGEN
IPO dateMar 13, 2019
CEORogers (Adam H)
Company Executives of Nervgen Pharma Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
+50000.00%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
109.76K
+100000.00%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
+50000.00%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
109.76K
+100000.00%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 9
Updated: Fri, Jan 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PFP Biosciences Holdings LLC
18.29%
Punnett, Harold
1.46%
Bayley (Brian E)
0.70%
Kaye (Randall E)
0.20%
Kelly (Michael)
0.18%
Other
79.17%
Shareholders
Shareholders
Proportion
PFP Biosciences Holdings LLC
18.29%
Punnett, Harold
1.46%
Bayley (Brian E)
0.70%
Kaye (Randall E)
0.20%
Kelly (Michael)
0.18%
Other
79.17%
Shareholder Types
Shareholders
Proportion
Other Insider Investor
18.29%
Individual Investor
2.87%
Other
78.84%
Institutional Shareholding
Updated: Fri, Jan 9
Updated: Fri, Jan 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
2
--
0.00%
-47.80K
2025Q4
2
--
0.00%
-47.80K
2025Q3
2
--
0.00%
-47.80K
2025Q2
2
--
0.00%
-47.80K
2025Q1
2
--
0.00%
-47.80K
2024Q4
2
--
0.00%
-47.80K
2024Q3
2
--
0.00%
-47.80K
2024Q2
3
44.40K
0.06%
-41.20K
2024Q1
2
3.40K
0.01%
-30.00K
2023Q4
2
3.40K
0.01%
-30.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PFP Biosciences Holdings LLC
14.69M
18.45%
+1.81M
+14.05%
Nov 19, 2025
Punnett, Harold
1.18M
1.48%
+50.00K
+4.44%
Jul 18, 2025
Bayley (Brian E)
565.00K
0.71%
+250.00K
+79.37%
Nov 19, 2025
Kaye (Randall E)
110.00K
0.14%
+100.00K
+1000.00%
Dec 09, 2025
Kelly (Michael)
143.96K
0.18%
--
--
Mar 28, 2025
Mckerracher (Krista L)
109.76K
0.14%
+100.00K
+1024.80%
Dec 04, 2025
Ruffolo (John)
70.41K
0.09%
--
--
Mar 28, 2025
Ives (Glenn Antony)
58.51K
0.07%
--
--
Mar 28, 2025
Rogers (Adam)
20.00K
0.03%
+10.00K
+100.00%
May 16, 2025
Mikol (Daniel D. M.D., Ph.D)
5.00K
0.01%
+5.00K
--
May 20, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
